NCT01511315View on ClinicalTrials.gov

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Psoriasis
Interventions
DRUG

Ustekinumab

Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.

Trial Locations (1)

94118

UCSF Psoriasis and Skin Treatment Center, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT01511315 - The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment | Biotech Hunter | Biotech Hunter